Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas, Daiichi Move Ahead With Factor Xa Programs

This article was originally published in PharmAsia News

Executive Summary

Astellas and Daiichi Sankyo both are on track to proceed to Phase III for their respective oral Factor Xa inhibitors, the companies indicated in second quarter earnings presentations on Nov. 7

You may also be interested in...



Daiichi Sankyo Completes Phase II, Moves To Phase III With Oral Factor Xa Inhibitor

TOKYO - Daiichi Sankyo said Dec. 8 that it would soon complete Phase II clinical trials of its oral Factor Xa inhibitor DU-176b, after it registered comparable safety and tolerability in non-valvular atrial fibrillation patients compared to those taking the anticoagulant warfarin

Daiichi Sankyo Completes Phase II, Moves To Phase III With Oral Factor Xa Inhibitor

TOKYO - Daiichi Sankyo said Dec. 8 that it would soon complete Phase II clinical trials of its oral Factor Xa inhibitor DU-176b, after it registered comparable safety and tolerability in non-valvular atrial fibrillation patients compared to those taking the anticoagulant warfarin

Daiichi Sankyo Forecasts Fall for Fiscal 2008 Due To Overseas Investments, R&D Growth

TOKYO - Profits for fiscal 2007 were lower than expected and earnings are to decline for fiscal 2008 "under the challenging environment such as the National Health Insurance drug price revisions and the stronger yen," said Takashi Shoda, president and CEO of Daiichi Sankyo at its headquarters in Tokyo, May 14. Shoda also cited the company's heavy investment in overseas facilities and its R&D growth as factors for the negative forecast

Related Content

UsernamePublicRestriction

Register

OM002075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel